S&P 500 7543.64 +0.81%
NASDAQ 26206.89 +1.30%
TASI 10808.43 -0.42%
Oil (WTI) 72.16 +0.11%
Oil (Brent) 76.50 +0.26%
VIX 15.77 -0.44%
Gold 4115.80 -0.60%
USD/SAR 3.75 +0.00%

Intellia Therapeutics, Inc.

NTLA · Healthcare · · USD
15.44 USD
0.00 (-8.31%)
● Updated 2026-07-10 16:11 Saudi Time ↻ Refresh
Short-term Mid-term Long-term

Fahodi Score BUY Mid-term (Position)

68
/ 100
Technical 75
Trend & RS 69
Momentum 84
Fundamental 22
Macro 78
Liquidity 41
ComponentScoreWeight
Technical 75.0 20%
Trend & RS 68.9 30%
Momentum 83.7 15%
Fundamental 22.2 10%
Macro 78.4 20%
Liquidity 41.1 5%

Trade Setup

Entry 15.44
Stop Loss 12.90 (16.4%)
Target 1 (1:1) 17.98 (+16.4%)
Target 2 (2:1) 20.52 (+32.9%)
ATR(14) 1.27 (8.2%)
Risk per Share 2.54
Reward:Risk 2:1

ATR-based levels. Adjust for support/resistance zones.

Factor Profile

Factor Score Z Bar
Value 73.7 +0.95
Momentum 83.7 +1.35
Quality 40.0 -0.40
Composite 65.8

Quality Scores

Piotroski F-Score 2 /9 — Weak
✗ ✗ ✗ ✗ ✓ ✓ ✗ ✗ ✗
1. Positive Net Income 2. Positive Roa 3. Positive Cfo 4. Quality Earnings 5. Lower Leverage 6. Higher Liquidity 7. No Dilution 8. Higher Gross Margin 9. Higher Asset Turnover
Altman Z-Score Insufficient Data

Valuation vs Peers Undervalued

MetricStockSectorvs Peers
P/E Ratio N/A 22.0 Inline
P/B Ratio 3.0 4.0 Below

Comparing against Healthcare median multiples.

Trading at a discount to sector peers — potential value opportunity.

Position Sizing — Kelly Criterion

4.8%
Recommended Size
44.65%
Full Kelly
22.32%
Half Kelly
5.0%
Max Cap (Moderate)

Kelly inputs derived from quant score 68/100. Estimated win rate 60%, avg win 9.1%, avg loss 3.6%. Position was capped at the moderate risk maximum. This is analytical output, not a recommendation to trade.

RECOVERY Regime: RECOVERY (20% confidence) — position size reduced 4%

Signal Summary STRONG BUY

3
Bullish Signals
1
Bearish Signals
49.45
RSI(14)
0.8385
MACD

Relative Strength (RS) WEAK RS

22
/ 99
RS Rating
O'Neil filter: <80
RS vs SPY ↑ RISING (-0.2% vs SPY 3M)
RS vs Sector INLINE (Healthcare)
RS New High No (3d since high)
Sector Outperformance +1.8% (3M)
RS Line — stock / SPY (90 bars)
← older newer →
RS vs SPY 50-day SMA of RS
WEAK RS: Underperformer — the stock is lagging the market. Avoid until RS trend reverses upward.

Technical Indicators

IndicatorValueSignal
Rsi 49.45 NEUTRAL
Macd 0.8385 BEARISH
Ma Cross 14.26 / 13.74 GOLDEN CROSS
Trend Short ABOVE SMA50
Trend Long ABOVE SMA200
Bollinger MIDDLE
Volume 1.13x NORMAL

Key Levels

LevelPrice
52-Week High28.25
Bollinger Upper19.06
SMA(200)13.74
SMA(50)14.26
SMA(20)15.6
Current Price15.44
Bollinger Lower12.15
52-Week Low7.95
ATR(14)1.27

Advanced Technical Analysis

Click to expand

Wyckoff Phase & Volume Spread Analysis

Wyckoff Phase

DISTRIBUTION A Confidence
75%
Buying Climax
Acc: 1.0  |  Dist: 3.0  |  Markup: 0.0  |  Markdown: 0.0

Volume Spread Analysis (last 5 bars)

DateSignalVolDescription
2026-07-02 Normal 0.64x Normal bar — no special VSA pattern
2026-07-06 Normal 0.59x Normal bar — no special VSA pattern
2026-07-07 Normal 0.49x Normal bar — no special VSA pattern
2026-07-08 No Supply 0.54x Low volume, narrow spread, firm close — no selling pressure
2026-07-09 Normal 1.13x Normal bar — no special VSA pattern

Ichimoku Cloud NEUTRAL

LineValueStatus
Tenkan-sen (9) 16.81 Above Kijun
Kijun-sen (26) 15.14 Base line
Senkou A 15.98 Leading span A
Senkou B 15.12 Leading span B
Cloud 15.12 – 15.98 Bullish (Green)
Price vs Cloud 15.44 Inside Cloud
Chikou Span 13.13 Bullish
Alignment Score 3/4 NEUTRAL

TTM Squeeze & Divergences

TTM Squeeze

SQUEEZE OFF No squeeze Momentum: BULLISH FADING
BB: 12.15 – 19.06  |  KC: 13.68 – 17.53

Divergences (last 60 bars)

TypeIndicatorBars AgoStrength
Hidden Bearish RSI 28

Anchored VWAP

VWAP: 13.02 Anchor: 2025-11-20 (52w Low) ABOVE AVWAP +18.6%

Heikin-Ashi Trend

WEAKLY BEARISH Full data via /api/advanced/NTLA

Valuation

MetricValue
Market Cap2.16B
P/E (TTM)N/A
Forward P/EN/A
P/B3.00
EPS-3.23

Financial Health

MetricValue
Revenue Growth-9.5%
Profit MarginN/A
ROE-56.3%
Debt/Equity12.96
Current Ratio6.10
Dividend YieldN/A
Payout RatioN/A
Beta1.77

Trading Data

15.44
Open
15.44
Day High
15.44
Day Low
7.35M
Volume (1.1x avg)

Recent News (8)

Intellia Therapeutics (NTLA) Could Be 37% Undervalued After Phase 3 Lonvo Z Success
Simply Wall St. · 2026-07-09
NTLA Surges 38% in a Month: Should You Buy, Sell or Hold the Stock?
Zacks · 2026-07-09
Intellia Therapeutics (NTLA) Stock Looks Rich On Sales But Weak On Returns
Simply Wall St. · 2026-07-09
Wall Street Doubles Down on Wolfspeed Short Positions Over Cash Burn Fears
Barchart · 2026-07-08
A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics
Motley Fool · 2026-07-08
Is Intellia Therapeutics, Inc. (NTLA) A Good Stock To Buy Now?
Insider Monkey · 2026-07-03
Wall Street Thinks This High-Flying Biotech Stock Can Soar Another 57%
Motley Fool · 2026-07-01
Strength Seen in Mirum Pharmaceuticals (MIRM): Can Its 5.5% Jump Turn into More Strength?
Zacks · 2026-06-29

Price Chart (90 Days)

Candlesticks (green=up, red=down) SMA 20 SMA 50 Bollinger Bands (upper/lower) Volume (green=buying, red=selling)
Powered by Fahodi Methodology. This is analytical output, not financial advice. Always do your own due diligence.  ·  Pipeline status  ·  Data: —